Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

被引：0

作者：

Kagawa, Y. ^{[1
]}

Satake, H. ^{[2
]}

Kato, T. ^{[3
]}

Oba, K. ^{[4
]}

Yasui, H. ^{[5
]}

Nakamura, M. ^{[6
]}

Watanabe, T. ^{[7
]}

Hirata, K. ^{[8
]}

Muro, K. ^{[9
]}

Komatsu, Y. ^{[10
]}

Yoshino, T. ^{[11
]}

Yamazaki, K. ^{[12
]}

Mishima, H. ^{[13
]}

Kotaka, M. ^{[14
]}

Tsuji, A. ^{[15
]}

Kakeji, Y. ^{[16
]}

Oki, E. ^{[17
]}

Nagata, N. ^{[18
]}

Junichi, S. ^{[19
]}

机构：

[1] Kansai Rosai Hosp, Surg, Amagasaki, Hyogo, Japan

[2] Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan

[3] Osaka Natl Hosp, Natl Hosp Org, Surg, Osaka, Japan

[4] Univ Tokyo, Dept Biostat, Tokyo, Japan

[5] Gen Hosp, Kobe City Med Ctr, Dept Med Oncol, Kobe, Hyogo, Japan

[6] Aizawa Hosp, Aizawa Comprehens Canc Ctr, Matsumoto, Nagano, Japan

[7] Himeji Hosp, Japanese Red Cross Soc, Dept Surg, Himeji, Hyogo, Japan

[8] Univ Occupat & Environm Hlth, Dept Surg, Kitakyushu, Japan

[9] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[10] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan

[11] Natl Canc Ctr Hosp, Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Shizuoka Canc Ctr, Dept GI Oncol, Shizuoka, Japan

[13] Aichi Med Univ, Dept Surg, Nagakute, Aichi, Japan

[14] Sano Hosp, Gastrointestinal Canc Ctr, Surg, Kobe, Hyogo, Japan

[15] Kagawa Univ, Fac Med, Grad Sch Med, Dept Clin Oncol, Takamatsu, Kagawa, Japan

[16] Kobe Univ, Grad Sch Med, Dept Surg, Div Gastrointestibal Surg, Kobe, Hyogo, Japan

[17] Kyushu Univ Hosp, Dept Surg, Fukuoka, Fukuoka, Japan

[18] Kitakyushu Gen Hosp, Dept Surg, Kitakyushu, Fukuoka, Japan

[19] Tokai Cent Hosp, Kakamigahara, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

107P

引用

页数：2

共 50 条

[41] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer (vol 76, pg 925, 2015)
Bendell, Johanna C.
Rosen, Lee S.
Mayer, Robert J.
Goldman, Jonathan W.
Infante, Jeffrey R.
Benedetti, Fabio
Lin, Donghu
Mizuguchi, Hirokazu
Zergebel, Christopher
Patel, Manish R.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (02) : 439 - 439
[42] Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
Toshihiko Doi
Takayuki Yoshino
Nozomu Fuse
Narikazu Boku
Kentaro Yamazaki
Wasaburo Koizumi
Ken Shimada
Yasutaka Takinishi
Atsushi Ohtsu
Investigational New Drugs, 2015, 33 : 1068 - 1077
[43] A phase Ib/II study of cetuximab and pembrolizumab in metastatic colorectal cancer
Fountzilas, C.
Mukherjee, S.
Saltzman, J.
Bajor, D.
Muhitch, J.
Abrams, S.
Maguire, O.
Minderman, H.
Wang, K.
Hutson, A.
Hicks, K.
Ventola, J.
Kalinski, P.
Iyer, R.
Boland, P.
ANNALS OF ONCOLOGY, 2020, 31 : S140 - S140
[44] Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
Doi, Toshihiko
Yoshino, Takayuki
Fuse, Nozomu
Boku, Narikazu
Yamazaki, Kentaro
Koizumi, Wasaburo
Shimada, Ken
Takinishi, Yasutaka
Ohtsu, Atsushi
INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1068 - 1077
[45] Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
Hiroshi Matsuoka
Takeshi Yamada
Ryo Ohta
Yoichiro Yoshida
Tatsuyuki Watanabe
Makoto Takahashi
Chihiro Kosugi
Atsuko Fukazawa
Hidekazu Kuramochi
Akihisa Matsuda
Hiromichi Sonoda
Hiroshi Yoshida
Suguru Hasegawa
Kazuhiro Sakamoto
Toshiaki Otsuka
Keiji Hirata
Keiji Koda
International Journal of Clinical Oncology, 2022, 27 : 1859 - 1866
[46] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Sugiura, Kiyoaki
Seo, Yuki
Takahashi, Takayuki
Tokura, Hideyuki
Ito, Yasuhiro
Tanaka, Motomu
Kishida, Norihiro
Nishi, Yusuke
Onishi, Yoshihiko
Aoki, Hikaru
BMC GASTROENTEROLOGY, 2021, 21 (01)
[47] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Kiyoaki Sugiura
Yuki Seo
Takayuki Takahashi
Hideyuki Tokura
Yasuhiro Ito
Motomu Tanaka
Norihiro Kishida
Yusuke Nishi
Yoshihiko Onishi
Hikaru Aoki
BMC Gastroenterology, 21
[48] Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
Matsuoka, Hiroshi
Yamada, Takeshi
Ohta, Ryo
Yoshida, Yoichiro
Watanabe, Tatsuyuki
Takahashi, Makoto
Kosugi, Chihiro
Fukazawa, Atsuko
Kuramochi, Hidekazu
Matsuda, Akihisa
Sonoda, Hiromichi
Yoshida, Hiroshi
Hasegawa, Suguru
Sakamoto, Kazuhiro
Otsuka, Toshiaki
Hirata, Keiji
Koda, Keiji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1859 - 1866
[49] Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study
Chen, Ye
Zhou, Yu-Wen
Cheng, Ke
Li, Zhi-Ping
Luo, De-Yun
Qiu, Meng
Li, Qiu
Wang, Xin
Shen, Ya-Li
Cao, Dan
Yang, Yu
Bi, Feng
Liu, Ji-Yan
Gou, Hong-Feng
ONCOLOGIST, 2021, 26 (08): : E1320 - E1326
[50] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
Yoichiro Yoshida
Takeshi Yamada
Hirohiko Kamiyama
Chihiro Kosugi
Keiichiro Ishibashi
Hiroshi Yoshida
Hideyuki Ishida
Satoru Yamaguchi
Hidekazu Kuramochi
Atsuko Fukazawa
Hiromichi Sonoda
Kazuhiko Yoshimatsu
Akihisa Matsuda
Suguru Hasegawa
Kazuhiro Sakamoto
Toshiaki Otsuka
Keiji Koda
International Journal of Clinical Oncology, 2021, 26 : 111 - 117

← 1 2 3 4 5 →